Key result
Bisoprolol transdermal patches significantly reduced the incidence of early recurrences of atrial arrhythmias at 3 months postablation compared to standard care (6.8% vs 25.7%, OR 0.181).
Why the study?
Early recurrences of atrial arrhythmias after ablation may require intervention, but optimal medical therapy to prevent them requires clarification.
Does bisoprolol transdermal patch prevent early recurrences of atrial arrhythmias in patients with paroxysmal atrial fibrillation undergoing their first ablation?
Cohort (n=203)
No
Does bisoprolol transdermal patch prevent early recurrences of atrial arrhythmias in patients with paroxysmal atrial fibrillation undergoing their first ablation?
The use of bisoprolol transdermal patches significantly reduced the incidence of early recurrences of atrial arrhythmias during the 3-month blanking period after first-time ablation for paroxysmal atrial fibrillation.
BTPs were associated with fewer ERAAs post-ablation; hypothesis-generating and requires RCTs before practice change.
Background Early recurrences of atrial arrhythmias (ERAAs) after ablation may require therapeutic intervention. The optimal medical therapy that prevents ERAAs requires clarification. This study aimed to compare the incidence of ERAAs between patients who received or did not receive bisoprolol transdermal patches (BTPs) at 3 months postablation. Methods This single‐center retrospective study enrolled 203 consecutive patients with paroxysmal atrial fibrillation (AF) who had undergone their first ablation, comprising 59 in the BTP group and 144 in the non‐BTP group. Follow‐up assessments were conducted monthly for 3 months. We evaluated the incidence of ERAAs. Results During the initial 1‐week observational period, the rate of ERAAs was lower in the BTP group (5.0%) than that in the non‐BTP group (18.8%) ( P = .013). At 3 months postablation, the rate of ERAAs was lower in the BTP group (6.8%) than that in the non‐BTP group (25.7%) ( P = .002). The cumulative freedom from ERAAs was significantly lower in the BTP group than in the non‐BTP group (log‐rank: P = .003). Administering BTPs was an independent factor that protected against ERAAs (odds ratio 0.181, [95% confidence interval 0.059‐0.559], P = .003). Conclusion BTPs may prevent ERAAs after ablation.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2021) conducted a cohort in Paroxysmal atrial fibrillation (n=203). Bisoprolol transdermal patch vs. Non-bisoprolol transdermal patch (historical control) was evaluated on Incidence of definite early recurrences of atrial arrhythmias (ERAAs) at 3 months postablation (OR 0.181, 95% CI 0.059-0.559, p=0.003). Bisoprolol transdermal patches significantly reduced the incidence of early recurrences of atrial arrhythmias at 3 months postablation compared to standard care (6.8% vs 25.7%, OR 0.181).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: